Therapeutic Solutions International, Inc., reported positive animal data in the 4T1 breast cancer model using its clinically tested StemVacs cellular immunotherapy. In a series of experiments, it was demonstrated that StemVacs administration resulted in a) regression of established breast cancer in mice; b) that regression was dependent on natural killer cells, and c) that immunity to breast cancer could be transferred by CD4 T cells to nave mice. Previously the Company announced positive safety data in 10 patients treated with StemVacs™. Additionally, the Company has filed an Investigational New Drug Application (IND) which is currently pending based on the Company responding to questions posed by the FDA.